Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality

In recent years, considerable advances concerning therapeutic strategies in patients with metastatic cancer have been achieved. Particularly in renal cell cancer (RCC) and advanced stage non-small cell lung cancer (NSCLC), immune-activating and antiangiogenic (AA) drugs (i.e., checkpoint antibodies...

Descripción completa

Detalles Bibliográficos
Autores principales: Pircher, Andreas, Wolf, Dominik, Heidenreich, Axel, Hilbe, Wolfgang, Pichler, Renate, Heidegger, Isabel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5713261/
https://www.ncbi.nlm.nih.gov/pubmed/29088109
http://dx.doi.org/10.3390/ijms18112291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5713261/
https://www.ncbi.nlm.nih.gov/pubmed/29088109
http://dx.doi.org/10.3390/ijms18112291

Ejemplares similares